Veracyte VCYT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $28.71M+307% | $41.15M+705% | $19.14M+26.3% | -$980K-117% | $7.05M+478% | ||
| $5.43M+1.3% | $5.3M-15.3% | $5.27M-10.4% | $5.49M-4.3% | $5.36M-4.1% | ||
| $12.76M+16.5% | $10.9M+13.2% | $10.76M+23.0% | $10.99M+11.5% | $10.96M+36.7% | ||
| -$366K— | —— | —— | -$15K+60.5% | $0+100% | ||
| $5.57M-21.1% | —— | —— | —— | $7.05M+9.2% | ||
| $2.59M-63.7% | -$492K+63.7% | -$3.66M-194% | -$4.01M-2,373% | $7.12M+561% | ||
| $132K+208% | -$194K— | -$1.72M-446% | $1.51M+2.6% | -$122K+52.9% | ||
| -$319K+44.7% | -$799K-102% | -$495K+66.6% | -$609K+56.3% | -$577K+45.2% | ||
| -$350K+82.1% | -$12.58M-1,460% | $0-100% | -$925K-208% | -$1.95M-39,180% | ||
| $35.22M+557% | $52.58M+114% | $44.76M+49.4% | $33.61M+13.6% | $5.36M+160% | ||
| $2.96M+62.8% | $3.78M-8.7% | $2.79M+24.5% | $1.29M-53.6% | $1.82M-14.8% | ||
| $125M+150% | $50M0.0% | $0— | $50M— | $50M— | ||
| -$127.96M-147% | -$5.43M+90.0% | —— | -$224K+91.9% | -$51.82M-1,900% | ||
| $2.74M-7.8% | $3.51M+7.5% | $5.79M-53.6% | $1.81M+40.4% | $2.97M0.0% | ||
| $9.36M-0.9% | $3.66M+11.8% | $2.81M+29.1% | $2.38M+82.7% | $9.45M+147% | ||
| -$6.63M-2.2% | -$149K— | —— | -$566K-5,045% | -$6.48M-650% | ||
| -$58K-178% | $12K+103% | $60K— | $573K+1,039% | $74K+169% | ||
| -$99.43M-88.1% | $47.02M— | $96.06M+152% | $33.39M+24.9% | -$52.87M-649% | ||
| $164K+35.5% | —— | $835K-29.7% | $1.43M+8,324% | $121K— | ||
| $614K-30.4% | $651K+83.9% | —— | —— | $882K— | ||
| -$350K+82.1% | -$12.58M-1,460% | $0-100% | -$925K-208% | -$1.95M-39,180% | ||
| $80K-95.0% | —— | —— | $3.47M+1,438% | $1.59M+349% | ||
| -$6.12M+31.2% | —— | $9.13M+45,525% | —— | -$8.89M+1.2% | ||
| $870K-62.1% | —— | —— | —— | $2.3M— | ||
| -$319K+44.7% | -$799K-102% | -$495K+66.6% | -$609K+56.3% | -$577K+45.2% | ||
| $1.31M-55.4% | —— | $956K+141% | $2.53M— | $2.93M+6.9% | ||
| $732K-19.0% | $702K-47.1% | $689K-48.6% | $696K-39.4% | $904K-20.6% | ||
| -$10K-167% | -$568K-134% | -$87K-569% | $59K-58.7% | $15K+113% | ||
| $125M+150% | $50M0.0% | $0— | $50M— | $50M— | ||
| $2.32M+137% | $1.48M+133% | $323K— | —— | $977K-44.3% | ||
| —— | $711.25K— | $711.25K— | $711.25K— | $711.25K— | ||
| -$319K+44.7% | -$799K-102% | -$495K+66.6% | -$609K+56.3% | -$577K+45.2% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $32.25M+810% | $48.8M+139% | $41.97M+51.4% | $32.32M+20.6% | $3.54M+132% | ||
| $32.25M+810% | $48.8M+139% | $41.97M+51.4% | $32.32M+20.6% | $3.54M+132% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Veracyte's cash flow data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.